Skip to content
Amgen
-
Amgen’s Repatha receives positive EU opinion for expanded cardiovascular use
Repatha lowers low-density lipoprotein cholesterol (LDL-C), a key risk factor for cardiovascular disease, alongside other measures to manage cardiovascular risk.
-
Amgen boosts US biomanufacturing with additional US$300M investment in Puerto Rico
Through this expansion, the company aims to strengthen advanced manufacturing capabilities, support workforce development, and generate hundreds of construction-related jobs.
-
Amgen targets acute myeloid leukemia with USD840M Dark Blue Therapeutics deal
Amgen’s latest acquisition is centered on Dark Blue’s lead candidate, DBT 3757, which specifically treats acute myeloid leukemia that affects bone marrow and blood cells.